clindamycin + daptomycin

Clindamycin + daptomycin is a combination of two antibiotics used off-label for the treatment of serious infections caused by Gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA). Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Daptomycin is a cyclic lipopeptide antibiotic that disrupts bacterial cell membrane potential, leading to rapid depolarization and cell death. This combination may be considered in cases where monotherapy has failed or resistance has developed, although it is not an established or widely recommended regimen. Both agents are individually approved for complicated skin and soft tissue infections and bacteremia due to susceptible organisms[1][2][3]. The rationale for combining these drugs includes their complementary mechanisms of action and potential synergistic effects against certain resistant strains.